Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AZTR Azitra	$0.92 -2.8%	$1.43	$0.81 ▼ $4.98	$3.26M	-1.62	2.08 million shs	26.38 million shs
ENTO Entero Therapeutics	$2.04 +0.5%	$1.49	$0.84 ▼ $2.78	$3.24M	0.8	5.23 million shs	163,315 shs
SKVI Skinvisible	$0.16	$0.21	$0.14 ▼ $0.85	$840K	2.05	2,255 shs	N/A
VRAX Virax Biolabs Group	$0.77 +3.2%	$0.85	$0.72 ▼ $7.63	$3.32M	1.66	79,735 shs	17,641 shs

7 Stocks to Buy And Hold Forever

Enter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AZTR Azitra	0.00%	-13.08%	-38.58%	-51.68%	-77.99%
ENTO Entero Therapeutics	0.00%	+11.48%	+40.47%	+78.99%	+61.90%
SKVI Skinvisible	0.00%	-3.29%	-31.61%	-25.28%	-66.85%
VRAX Virax Biolabs Group	0.00%	-0.65%	-25.73%	-25.00%	-88.05%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
AZTR Azitra	1.3053 of 5 stars	0.0	5.0	0.0	0.0	3.3	0.0	0.6
ENTO Entero Therapeutics	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
SKVI Skinvisible	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
VRAX Virax Biolabs Group	3.2079 of 5 stars	3.5	5.0	0.0	0.0	0.0	1.7	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
AZTR Azitra	0.00	N/A	N/A	N/A
ENTO Entero Therapeutics	0.00	N/A	N/A	N/A
SKVI Skinvisible	0.00	N/A	N/A	N/A
VRAX Virax Biolabs Group	3.00	Buy	$3.00	292.16% Upside

Current Analyst Ratings Breakdown

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
AZTR Azitra	$10K	325.92	N/A	N/A	$4.97 per share	0.19
ENTO Entero Therapeutics	N/A	N/A	N/A	N/A	($2.45) per share	N/A
SKVI Skinvisible	$20K	42.07	N/A	N/A	($1.86) per share	-0.08
VRAX Virax Biolabs Group	$10K	332.01	N/A	N/A	$1.26 per share	0.61

Compare Profitability & Earnings

Company	Net Income	EPS	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
AZTR Azitra	-$8.97M	N/A	N/A	N/A	N/A	-183.57%	-138.65%	11/11/2025 (Estimated)
ENTO Entero Therapeutics	-$18.06M	N/A	∞	N/A	N/A	-1,063.82%	-17.94%	11/11/2025 (Estimated)
SKVI Skinvisible	-$570K	-$0.08	∞	N/A	-2,635.00%	N/A	-351.46%	N/A
VRAX Virax Biolabs Group	-$6.06M	N/A	∞	N/A	N/A	N/A	N/A	10/1/2025 (Estimated)

Latest SKVI, ENTO, AZTR, and VRAX Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue	Details
8/14/2025	Q2 2025	ENTO Entero Therapeutics	N/A	-$0.42	N/A	-$0.21	N/A	N/A
8/13/2025	Q2 2025	SKVI Skinvisible	N/A	-$0.05	N/A	-$0.05	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
AZTR Azitra	N/A	N/A	N/A	N/A	N/A
ENTO Entero Therapeutics	N/A	N/A	N/A	N/A	N/A
SKVI Skinvisible	N/A	N/A	N/A	N/A	N/A
VRAX Virax Biolabs Group	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
AZTR Azitra	N/A	1.24	1.24
ENTO Entero Therapeutics	N/A	2.81	2.81
SKVI Skinvisible	N/A	0.01	0.01
VRAX Virax Biolabs Group	N/A	7.27	7.13

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
AZTR Azitra	11.16%
ENTO Entero Therapeutics	12.30%
SKVI Skinvisible	N/A
VRAX Virax Biolabs Group	8.61%

Insider Ownership

Company	Insider Ownership
AZTR Azitra	0.25%
ENTO Entero Therapeutics	0.75%
SKVI Skinvisible	53.00%
VRAX Virax Biolabs Group	45.10%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
AZTR Azitra	10	3.53 million	3.52 million	Not Optionable
ENTO Entero Therapeutics	9	1.59 million	1.58 million	N/A
SKVI Skinvisible	2	5.40 million	2.54 million	Not Optionable
VRAX Virax Biolabs Group	5	4.34 million	2.38 million	Not Optionable

SKVI, ENTO, AZTR, and VRAX Headlines

Recent News About These Companies

Virax Biolabs Appoints Iain Miller, PhD as Independent Director to Accelerate Commercial Strategy

July 29, 2025 | prnewswire.com

Virax Biolabs Group Limited (VRAX) Latest Stock News & Headlines ...

July 22, 2025 | finance.yahoo.com

Virax BioLabs Group Limited: Virax Biolabs Announces Receipt of NASDAQ Notification Letter Regarding Minimum Bid Price Deficiency

July 20, 2025 | finanznachrichten.de

Virax Biolabs Announces Receipt of NASDAQ Notification Letter Regarding Minimum Bid Price Deficiency

July 18, 2025 | prnewswire.com

HC Wainwright & Co. Initiates Coverage of Virax Biolabs Group (VRAX) with Buy Recommendation

March 31, 2025 | msn.com

Virax Biolabs' Investigational Diagnostic Tests Has An Attractive Market Opportunity', Analyst Initiates With Buy Rating

March 31, 2025 | benzinga.com

Virax Biolabs Launches Clinical Study on T Cell Dysfunction

March 18, 2025 | msn.com

Virax Biolabs Enrolls First Patients in Clinical Study Assessing T cell Dysfunction in Post-acute Infection Syndromes

March 18, 2025 | prnewswire.com

Virax Biolabs Presents Data on T-Cell Dysfunction in Post-acute Infection Syndromes at the 19th World Immune Regulation Meeting

March 13, 2025 | prnewswire.com

Virax Biolabs to Present at 19th World Immune Regulation Meeting

March 5, 2025 | prnewswire.com

Virax Biolabs Aligns with US Health Department on Vaccine Transparency

February 25, 2025 | tipranks.com

Virax Biolabs Believes Technology Aligns with United States Department of Health and Human Services' Transparency Priority on Vaccine Efficacy

February 25, 2025 | prnewswire.com

Cosmos Health expands distribution of Avian Influenza kits

January 23, 2025 | msn.com

Cosmos Health Signs Expanded Exclusive Distribution Agreement with Virax Biolabs for Avian Influenza Virus PCR Kits in Saudi Arabia, the UAE, Qatar, and Kuwait

January 23, 2025 | accessnewswire.comA

Cosmos Health Secures Exclusive Distribution Agreement with Virax Biolabs for Avian Influenza Virus PCR Kits in Greece and Cyprus, with Additional Rights in Select European and GCC Countries

January 13, 2025 | accesswire.comA

Virax Biolabs Group Ltd (VRAX) Stock: Beyond the Surface of Its Performance?

December 19, 2024 | bovnews.comB

Virax Biolabs Announces Strategic Goals and Developments for 2025

December 18, 2024 | markets.businessinsider.com

Virax Biolabs' CEO James Foster Issues Letter to Shareholders

December 17, 2024 | prnewswire.com

Virax Biolabs Announces Agreement with Tebubio to Expand Distribution of ImmuneSelect Across the European Union, Norway, and Switzerland

December 10, 2024 | prnewswire.com

Virax Biolabs Sees Asset Growth Amid Financial Loss

November 22, 2024 | markets.businessinsider.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

SKVI, ENTO, AZTR, and VRAX Company Descriptions

Azitra NYSEAMERICAN:AZTR

$0.92 -0.03 (-2.81%)

Closing price 08/22/2025 04:10 PM Eastern

Extended Trading

$0.93 +0.00 (+0.29%)

As of 08/22/2025 07:59 PM Eastern

Azitra, Inc., an early-stage biopharmaceutical company, develops therapies for precision dermatology using engineered proteins and live biotherapeutic products to treat skin diseases. It develops ATR-12, a genetically modified strain of S. epidermidis, which is in Phase Ib clinical trial for treating Netherton syndrome, a skin disease. The company also develops ATR-04, a genetically modified strain of S. epidermidis for treating the papulopustular rash experienced by cancer patients undergoing epidermal growth factor receptor inhibitor; and ATR-01, an engineered recombinant human filaggrin protein for treating ichthyosis vulgaris, a skin disease. It has a collaboration with Bayer. The company was incorporated in 2014 and is based in Branford, Connecticut.

Entero Therapeutics NASDAQ:ENTO

$2.04 +0.01 (+0.49%)

Closing price 08/22/2025 04:00 PM Eastern

Extended Trading

$2.04 +0.00 (+0.25%)

As of 08/22/2025 07:51 PM Eastern

Entero Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of targeted and orally delivered therapies for the treatment of patients with gastrointestinal diseases. The company's pipeline candidates include latiglutenase, a targeted oral biotherapeutic for celiac disease designed to breakdown gluten into non-immunogenic peptides, currently under Phase 2 studies; and capeserod, a selective 5-HT4 receptor partial agonist under Phase 1 studies for the treatment of gastroparesis. It is also involved in the development of adrulipase, a recombinant lipase enzyme designed to enable the digestion of fats and other nutrients, currently under Phase 2 studies for the treatment of exocrine pancreatic insufficiency in patients with cystic fibrosis and chronic pancreatitis; and niclosamide, an oral small molecule with anti-inflammatory inhibitor therapy, currently under Phase 2 studies for the treatment of ulcerative proctitis and ulcerative proctosigmoiditis, as well as immune checkpoint inhibitor-associated colitis and diarrhea in metastatic cancer patients. The company was formerly known as First Wave BioPharma, Inc. and changed its name to Entero Therapeutics, Inc. in May 2024. Entero Therapeutics, Inc. was incorporated in 2014 and is based in Boca Raton, Florida.

Skinvisible OTCMKTS:SKVI

$0.16 0.00 (0.00%)

As of 08/22/2025

Skinvisible, Inc., together with its subsidiaries, focuses on the development, manufacture, and sale of topical, transdermal, and mucosal polymer-based delivery system technologies and formulations for use in pharmaceutical, over-the-counter, personal skincare, and cosmetic arenas. Its non-dermatological formulations offer solutions for women's health, pain management, and other markets. The company's flagship product is Invisicare, a patented polymer delivery system technology that enhances the delivery of active ingredients for topically applied skin care products. It also develops and licenses prescription and over-the-counter products to pharmaceutical and consumer goods companies; assists pharmaceutical clients in the early development of the formulations; and provides solutions to pharmaceutical companies by reformulating their products coming off patent with a new Invisicare patent, and new product benefits and line extensions. The company was formerly known as Microbial Solutions, Inc. and changed its name to Skinvisible, Inc. in February 1999. Skinvisible, Inc. was incorporated in 1998 and is based in Las Vegas, Nevada.

Virax Biolabs Group NASDAQ:VRAX

$0.76 +0.02 (+3.21%)

Closing price 08/22/2025 03:59 PM Eastern

Extended Trading

$0.78 +0.02 (+1.96%)

As of 08/22/2025 05:59 PM Eastern

Virax Biolabs Group Limited, a biotechnology company, sells, distributes, and markets diagnostics test kits for the prevention, detection, diagnosis, and risk management of viral diseases in the field of immunology. The company provides rapid antibody IgC/IgM tests, antigen tests, polymerase chain reaction rapid tests, and neutralizing antibody tests under the ViraxClear brand name. It also develops T-Cell IVD test kit for COVID-19, which intend to adapt for immunological profiling against multiple viral threats under the ViraxImmune Brand, as well as a proprietary mobile application for ViraxImmune that presents an individual's immunological profiling data and provide advice on the users' immune system. It serves clinics, pharmacies, laboratories, hospitals, and other groups, as well as corporations, pharmaceutical companies, research institutions, hospital systems, and public and private institutions. The company operates in Europe, South America, the Asia Pacific, Sub-Saharan Africa, and internationally. The company was formerly known as Virax Biolabs (Cayman) Limited and changed its name to Virax Biolabs Group Limited in September 2021. Virax Biolabs Group Limited was incorporated in 2021 and is headquartered in London, the United Kingdom.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time